Cour Pharmaceutical
Last updated: July 11, 2025
CEO - John Puisis
Country: USA | Funding: $135.5M (+)
Website: http://www.courpharma.com/
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
Website: http://www.courpharma.com/
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
